INTERIM RESULTS FROM A NATIONAL MULTICENTER PHASE II TRIAL OF COMBINATION BACILLUS CALMETTE-GUERIN PLUS INTERFERON ALFA-2B FOR SUPERFICIAL BLADDER CANCER-Reference-Cited by-同舟云学术

INTERIM RESULTS FROM A NATIONAL MULTICENTER PHASE II TRIAL OF COMBINATION BACILLUS CALMETTE-GUERIN PLUS INTERFERON ALFA-2B FOR SUPERFICIAL BLADDER CANCER

Published:2004-09 Issue:3 Volume:172 Page:888-893
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

O’DONNELL MICHAEL A.,LILLI KATHLEEN,LEOPOLD CHRISTINA,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference16 articles.

1. O’Donnell, M.A.: New therapeutic strategies for non-muscle-invasive (superficial) bladder cancer. AUA Update Series, XXII, lesson 2, 2003

2. Maintenance bacillus Calmette-Guerin immunotherapy in recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study;Lamm;J Urol,2000

3. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials;Silvester;J Urol,2002

4. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity;Böhle;J Urol,2003

5. Prognostic value of a T helper 1 urinary cytokine respońse after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer;Saint;J Urol,2002

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experimental and New Approaches for Bladder Preservation in Intermediate and High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC);Research and Reports in Urology;2024-04

2. Effect of anti-COVID-19 drugs on patients with cancer;European Journal of Medicinal Chemistry;2024-03

3. Complications of Intravesical Therapy for Early Bladder Tumors;Complications of Cancer Therapy: Best Practices in Prevention and Management;2024

4. OncoTherad® (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette–Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway;International Journal of Molecular Sciences;2023-12-15

5. BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets;International Journal of Molecular Sciences;2023-08-09